Table 5.

Adverse drug reactions in past 4 weeks of 1049 SHIP participants with schizophrenia or schizo-affective disorder who reported using any antipsychotic medication in the past 4 weeks, by use of clozapine

	Clozapine
	No		Yes
	n	%	n	%	Adjusted OR†	CI
Trembling/shaking	222	28.5	47	18.7	0.581**	0.405–0.832
Daytime drowsiness	393	50.4	143	56.7	1.379*	1.030–1.847
Dry or watery mouth	300	38.5	160	63.5	2.721***	2.016–3.674
Difficulty swallowing	91	11.7	46	18.3	1.754**	1.180–2.607
Skin rashes	61	7.9	18	7.2	0.930	0.533–1.623
Increased dreaming	177	22.9	39	15.5	0.675*	0.458–0.994
Swollen tender chest	35	4.6	6	2.4	0.519	0.213–1.266
Nauseous/feeling sick	122	15.7	51	20.2	1.396	0.964–2.021
Constipation	119	15.3	66	26.4	1.996***	1.404–2.836
Increased sweating	123	15.8	47	18.7	1.269	0.869–1.853
Dizziness/vertigo	156	20.0	71	28.2	1.571**	1.125–2.193
Palpitations	95	12.2	44	17.6	1.543*	1.034–2.303
Change in interest in sex	127	16.4	45	18.1	1.181	0.806–1.730
Sexual dysfunction	86	11.3	29	11.8	1.055	0.668–1.667
Period pain/change in frequency of periods	50	17.5	7	8.8	0.482	2.07–1.125

SHIP, survey of high impact psychosis; OR, odds ratio; CI, confidence interval.

Missing cases: trembling/shaking, daytime drowsiness, dry or watery mouth, increased sweating, dizziness/vertigo = 18; difficulty swallowing, nauseous/feeling sick = 19; skin rashes = 23; increased dreaming = 25; swollen, tender chest = 39; constipation, palpitations = 21; change in interest in sex = 26; sexual dysfunction = 40; period pain/change in frequency of periods = 684.

^†All variables are adjusted for chronicity and diagnosis.

*p < 0.05, **p < 0.01, and ***p < 0.001.